



## **Jazz Pharmaceuticals Announces Public Offering of Common Stock**

May 10, 2010

PALO ALTO, Calif., May 10, 2010 /PRNewswire via COMTEX/ --Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that it is offering to sell 7 million shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. All of the shares in the offering are to be sold by Jazz Pharmaceuticals. Barclays Capital Inc. is the sole book-running manager of the offering. Jazz Pharmaceuticals intends to use all of the net proceeds from the offering to repay a portion of its outstanding senior secured notes.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state in which such offer, solicitation or sale is not permitted. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from: Barclays Capital Inc., c/o Broadridge, Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, New York 11717; Barclaysprospectus@broadridge.com (phone: 888-603-5847).

The issuer has filed a registration statement (including a base prospectus) with the Securities and Exchange Commission, or SEC, for an offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and related prospectus supplements, and the other documents that the issuer has filed or will file with the SEC for more complete information about the issuer and this offering. You may access these documents when available for free by visiting EDGAR on the SEC website at [www.sec.gov](http://www.sec.gov). Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.

### **About Jazz Pharmaceuticals, Inc.**

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

### **"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995**

This press release contains forward-looking statements, including, but not limited to, statements related to the completion of the public offering. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties related to completion of the public offering. There can be no assurance that Jazz Pharmaceuticals will be able to complete the public offering. Additional risks and uncertainties relating to the public offering, Jazz Pharmaceuticals and its business can be found under the heading "Risk Factors" in Jazz Pharmaceuticals' Quarterly Report on Form 10-Q for the quarter ended March 31, 2010, filed with the Securities and Exchange Commission (SEC) on May 6, 2010, and in the preliminary prospectus supplement related to the public offering to be filed with the SEC on May 10, 2010. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

SOURCE Jazz Pharmaceuticals, Inc.